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with a neutralizing IL-17 mAb also re-
sulted in increased lung CFU, and IL-22-
deficient mice were resistant to infection.
Lungs from infected IL-17- and IL-17R-
deficient mice contained substantially
reduced amounts of G-CSF, neutrophil
recruitment and cellular infiltration as
could be expected, but this may not
have been the reason for the failure in
protection. Instead the authors showed
that IL-17 and IL-17R-deficient mice had
strongly reduced expression of IFN-g
and IL-12p35 mRNA indicating that IL-17
was somehow required for the generation
of a Th1 response (Figure 1). Their next
series of experiments demonstrated that
IL-17, either in the absence or presence
of LVS, could directly induce the produc-
tion of IL-12, IFN-g, IL-6, KC and MIP-1a
in bone marrow-derived DC (BMDC),
sorted lung CD11c+ cells, bone marrow-
derived macrophages (BMDM), and
freshly isolated alveolar macrophages.
Coculture experiments of BMDC with
naive OT-II transgenic T cells and OVA
peptide showed that IL-17 could induce
the polarization of these naive T cells into
IFN-g-producing Th1 cells. BMDC from
IL-12p40-, IL-17R- and IFN-g-deficient
mice could not support this effect of IL-17
on T cell differentiation, indicating that it
was specific and mediated through
induction of IL-12 and IFN-g.
These results demonstrate the IL-17
can regulate IL-12-Th1 cell immunity
against an intracellular pathogen. This
now turns the attention to the early events
following infection as they set the stage
for the ensuing immune response. The
signals that give rise to IL-12 and IL-23
production by the DC will be important
for determining a protective immune re-
sponse. Are these cytokines produced
by different types of DCs?
Timing is also an important factor be-
cause the induction of IL-12 and IFN-g
by IL-17 is a rapid and early event. The
authors show that IL-17 is produced by
antigen-specific T cells and by gd T cells,
which are part of the innate immune cells.
Are the requirements for these cell types
to produce IL-17 similar or different?
And how do the IL-17-IFN-g double
producing T cells fit in? Without doubt,
future investigations will focus on these
and other aspects of the interaction
between Th17 and Th1 cell pathways.
These interactions will likely be complex
because in the absence of DC, IL-17 has
been shown to inhibit Th1 differentiation
(O’Connor et al., 2009). However, this
work now opens up insights in the IL-23-
Th17 and IL-12-Th1 pathways and shows
that there is not only counter-regulation
but also interdependence.
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In this issue of Immunity, Turtle et al. (2009) describe the identification of a distinct CD8+memory T cell subset
in humans, which could bring us closer to the identification of the enigmatic ‘‘memory stem cell.’’CD8+ T cells can confer protective immu-
nity toward (intracellular) pathogens and
some cancers. In order to maintain
protection, long-living memory T cells are
generated, which might persist through-
out an individual’s lifespan, probably
without the need to re-encounter antigen
(Williams and Bevan, 2007). The develop-702 Immunity 31, November 20, 2009 ª200ment of chronic disease after infection
with common viruses such as cytomega-
lovirus (CMV) or Epstein-Barr virus (EBV)
is prevented by the constitutive presence
of virus-specific CD8+ effector cells.
Similarly, CD8+ T cells are believed to
contribute to virus control in long-term
nonprogressing HIV-infected individuals.9 Elsevier Inc.How exactly CD8+ T cells are maintained
beyond the contraction phase of an
immune response is still only poorly
understood. With the identification of
functionally and phenotypically distinct
subsets of memory T cells (Sallusto
et al., 1999), however, a division of labor
in between different cell types has
Immunity
PreviewsCD8+ memory T cell subsets
Chemotherapy
ABCB1+CD161hiIL-18Rαhi
c-kit+Bcl-2+Bcl-xL+
CD127+CD28+
Normal conditions Lymphopenia Reconstitution
Memory stem cell?
Figure 1. CD161hiIL-18Rhi Memory T Cells Are Important for Reconstitution of the Memory T Cell Compartment
CD161hiIL-18Rhi CD8+ memory T cells are resistant to chemotherapy because of their expression of ATP-binding cassette (ABC)-superfamily multidrug efflux
proteins (e.g., ABCB1). They are quiescent but have the capability of self renewal and proliferation and can differentiate into other cell subsets. These cells
express stem cell-associated markers (c-kit), as well as antiapoptotic and survival proteins (Bcl-2 and Bcl-xL) or receptors (CD127). This particular subset of
memory T cells might not only play a crucial role for immune reconstitution upon chemotherapy-induced lymphopenia, it could also be relevant for T cell memory
maintenance under normal conditions.become evident. The entire diversity of
these subsets can be generated from
a single naive precursor cell, and out of
adoptively transferred single-cell-derived
daughter cells, complex secondary
immune responses can evolve (Stem-
berger et al., 2007). These findings—the
enormous plasticity of CD8+ T cell differ-
entiation and the maintenance of this
plasticity within specialized memory
Tcell populations—have initiatedadebate
about whether a ‘‘memory stem cell’’
exists. In the mouse, some phenotypical
and molecular signatures (e.g., Wnt
signaling) (Gattinoni et al., 2009) with simi-
larities to naive T cells as well as hemato-
poetic stem cells (HSCs) have been found
in distinct subsets of memory T cells,
which in some cases might reside in
specialized niches in the bone marrow
(Mazo et al., 2005; Tokoyoda et al., 2009).
However, a more conclusive definition of
‘‘memory stem cells’’ including (life-long)
self-renewing capacity, which would have
to be based on serial adoptive transfer
experiments, still remains elusive.
The starting point of the studies by
Turtle et al. (2009) in this issue of Immunity
is the long-known clinical observation that
repeated induction of profound lympho-
cytopenia in patients undergoing multiple
cycles of cytotoxic chemotherapy only
infrequently results in severe infections
with viruses that can be controlled by
memory T cells (such as CMV or EBV);
this indicates that like HSCs, some CD8+
memory T cells might be more resistant
to chemotherapy and that they are
fully capable of conferring or reconstitut-
ing protective immunity. The mechanisms
by which HSCs are resistant to chemo-therapyare related tobothcell quiescence
and the overexpression of ATP-binding
cassette (ABC)-superfamily multidrug
efflux proteins (e.g., ABCB1), which
protect cells from toxic xenobiotics and
endogenous metabolites. The authors
initially searched for memory T cells able
to efflux drugs or dyes that are substrates
of the ABCB1 transporter, and they not
only succeeded in identifying a small frac-
tion of rapidly effluxing cells within the
central memory (Tcm) and effector
memory (Tem) compartments, they also
uncovered two surface markers—namely
CD161 and IL-18 receptor (IL-18R)—that
allow selective labeling and further anal-
ysis of this unique human CD8+ memory
subset. CD161hiIL-18Rhi cells preferen-
tially survive exposure to chemotherapy
in vitro and in vivo, are relatively quiescent
but demonstrate proliferation and self-
renewal in response to cytokines that
maintain homeostasis, and differentiate
in response to antigen stimulation into
other effector and memory T cell subsets
(Figure 1). In line with these characteris-
tics, the uniquememory subset expresses
higher amounts of c-kit, Bcl-2, CD28,
CD127, and Bcl-xL than other T cell
subsets. Most importantly, within the
CD161hiIL-18Rhi subset, virus-specific
CD8+ T cells are readily detectable, and
this cell type accumulates in theperipheral
blood of patients shortly after chemo-
therapy, providing strong evidence that
these cells are indeed crucially involved
in providing protection and immune
reconstitution.
Initial functional and phenotypic anal-
ysesof theCD161hiIL-18RhiCD8+memory
T cell subset suggest that it is involvedImmunity 31,in clinically relevant situations such as
immune reconstitution upon chemo-
therapy-induced lymphopenia. However,
as the authors themselves state, a more
conclusive demonstration of stem cell-
like characteristics of this subset (such
as serial adoptive transfers) will be
required before a clear link to ‘‘memory
stem cells’’ can be drawn; this will also
require transmissionof the findings to suit-
able animal models, where more conclu-
sive experiments can be performed.
Regardless of these limitations, with the
currently available data it is tempting to
speculate that the CD161hiIL-18Rhi CD8+
memory T cell subset is not only a crucial
subset for immune reconstitution during
temporary lymphopenia but also a central
player in the maintenance of CD8+ T cell
memory in healthy individuals. With their
stem cell-like character, the CD161hiIL-
18Rhi subsetmight becapable of constitu-
tively feeding the pool of lifespan-limited
and functionally diverse (effector) memory
progenitor cells. In this case,maintenance
of immunity by memory stem cells could
be achieved by asymmetric cell division,
as has been described for HSCs.
CD161hiIL-18Rhi CD8+ memory T cells
are found in low numbers circulating in
the peripheral blood of healthy individuals,
which might indicate that they do not
need a specific niche for survival and
self-renewal. Because CD161hiIL-18Rhi
CD8+ memory T cells share homing re-
ceptors with Tcm and Tem cells, they will
most likely migrate to similar sites while
searching for their cognate antigen. Other
groups have recently described that like
plasma memory B cells, some CD8+ and
CD4+ memory T cells are maintained inNovember 20, 2009 ª2009 Elsevier Inc. 703
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(Mazo et al., 2005; Tokoyoda et al., 2009).
Thus, the CD161hiIL-18Rhi CD8+ memory
T cell subset could also represent an early
progenitor population released from true
memory stem cells sitting in the bone
marrow or other survival sites. In this case,
cell subsets with the potential for immune
reconstitution and long-term survival
should preferentially be present within
the more weakly differentiated Tcm cell
compartment, which has also been
demonstrated by Riddell and colleagues
in primate studies (Berger et al., 2008).
However, the even higher presence of
the CD161hiIL-18Rhi CD8+ memory T cell
subset within the Tem cells does not fit
that well into such a model. Therefore, it
will be important to analyze whether
bone-marrow-residing CD8+ memory
cells are distinct from the circulating
CD161hiIL-18Rhi CD8+ memory T cell
subset and out of which compartment
(Tcm or Tem cell) reconstituting cell
populations really arise. Unraveling the
exact relationship between different cell
subsets as well as the identification of
the underlying survival factors and micro-
anatomical locations will become a major
task for future research in the field.
Furthermore, it will be interesting to inves-
tigate whether similar ‘‘stem cell-like’’
subsets can be found for other lympho-
cytes such as CD4+ T cells, NK cells, or
B cells.704 Immunity 31, November 20, 2009 ª2009The identification of a specific long-
living CD8+ T cell subpopulation that is
chemotherapy resistant and can reconsti-
tute pre-existing immunity has important
clinical implications, especially for vacci-
nation and adoptive immunotherapy.
The detection of CD161hiIL-18Rhi CD8+
memory T cells after vaccination might
allow monitoring of a sustained immune
response and could help to improve inef-
fective vaccination strategies. For adop-
tive immunotherapy with ex vivo-isolated
(Knabel et al., 2002) or in vitro-expanded
cells, the presence of this unique cell
population in the transplant should be
advantageous for sustained therapeutic
effects; if this holds true, the presence of
CD161hiIL-18Rhi CD8+ memory T cells
could be used to identify optimal donors
and might become an important quality
control measure for clinical T cell
products. Additional evidence for this
assumption has just been provided
by theobservation that uponbonemarrow
transplantations, the phenotype of donor-
derived CMV-specific CD8+ T cells,
especially the presence of a subset of
CD27+CD57 memory T cells (a surface
expression pattern also shared by
CD161hiIL-18Rhi cells), positively corre-
lates with a lower risk to develop post-
transplant CMV-associated complica-
tions (Scheinberg et al., 2009). Obviously,
this is going to be an exciting and clinically
important area for future research.Elsevier Inc.REFERENCES
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